A citation-based method for searching scientific literature

A Keech, R J Simes, P Barter, J Best, R Scott, M R Taskinen, P Forder, A Pillai, T Davis, P Glasziou, P Drury, Y A Kesäniemi, D Sullivan, D Hunt, P Colman, M d'Emden, M Whiting, C Ehnholm, M Laakso. Lancet 2005
Times Cited: 2081







List of co-cited articles
1692 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Effects of combination lipid therapy in type 2 diabetes mellitus.
Henry N Ginsberg, Marshall B Elam, Laura C Lovato, John R Crouse, Lawrence A Leiter, Peter Linz, William T Friedewald, John B Buse, Hertzel C Gerstein, Jeffrey Probstfield,[...]. N Engl J Med 2010
43

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Deepak L Bhatt, P Gabriel Steg, Michael Miller, Eliot A Brinton, Terry A Jacobson, Steven B Ketchum, Ralph T Doyle, Rebecca A Juliano, Lixia Jiao, Craig Granowitz,[...]. N Engl J Med 2019
41

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Gregory G Schwartz, P Gabriel Steg, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Rafael Diaz, Jay M Edelberg, Shaun G Goodman, Corinne Hanotin, Robert A Harrington,[...]. N Engl J Med 2018
26

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
Marc S Sabatine, Robert P Giugliano, Anthony C Keech, Narimon Honarpour, Stephen D Wiviott, Sabina A Murphy, Julia F Kuder, Huei Wang, Thomas Liu, Scott M Wasserman,[...]. N Engl J Med 2017
24

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
William E Boden, Jeffrey L Probstfield, Todd Anderson, Bernard R Chaitman, Patrice Desvignes-Nickens, Kent Koprowicz, Ruth McBride, Koon Teo, William Weintraub. N Engl J Med 2011
22

Effects of extended-release niacin with laropiprant in high-risk patients.
Martin J Landray, Richard Haynes, Jemma C Hopewell, Sarah Parish, Theingi Aung, Joseph Tomson, Karl Wallendszus, Martin Craig, Lixin Jiang, Rory Collins,[...]. N Engl J Med 2014
947
22

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
Christopher P Cannon, Michael A Blazing, Robert P Giugliano, Amy McCagg, Jennifer A White, Pierre Theroux, Harald Darius, Basil S Lewis, Ton Oude Ophuis, J Wouter Jukema,[...]. N Engl J Med 2015
21

Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study.
Aruna D Pradhan, Nina P Paynter, Brendan M Everett, Robert J Glynn, Pierre Amarenco, Marshall Elam, Henry Ginsberg, William R Hiatt, Shun Ishibashi, Wolfgang Koenig,[...]. Am Heart J 2018
149
21


2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
François Mach, Colin Baigent, Alberico L Catapano, Konstantinos C Koskinas, Manuela Casula, Lina Badimon, M John Chapman, Guy G De Backer, Victoria Delgado, Brian A Ference,[...]. Eur Heart J 2020
18

Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.
Mitsuhiro Yokoyama, Hideki Origasa, Masunori Matsuzaki, Yuji Matsuzawa, Yasushi Saito, Yuichi Ishikawa, Shinichi Oikawa, Jun Sasaki, Hitoshi Hishida, Hiroshige Itakura,[...]. Lancet 2007
16

Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial.
Stephen J Nicholls, A Michael Lincoff, Michelle Garcia, Dianna Bash, Christie M Ballantyne, Philip J Barter, Michael H Davidson, John J P Kastelein, Wolfgang Koenig, Darren K McGuire,[...]. JAMA 2020
135
16

Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.
Louise Bowman, Marion Mafham, Karl Wallendszus, Will Stevens, Georgina Buck, Jill Barton, Kevin Murphy, Theingi Aung, Richard Haynes, Jolyon Cox,[...]. N Engl J Med 2018
277
14

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
C Baigent, L Blackwell, J Emberson, L E Holland, C Reith, N Bhala, R Peto, E H Barnes, A Keech, J Simes,[...]. Lancet 2010
14

Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer.
JoAnn E Manson, Nancy R Cook, I-Min Lee, William Christen, Shari S Bassuk, Samia Mora, Heike Gibson, Christine M Albert, David Gordon, Trisha Copeland,[...]. N Engl J Med 2019
358
13

Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease.
Brian A Ference, John J P Kastelein, Kausik K Ray, Henry N Ginsberg, M John Chapman, Chris J Packard, Ulrich Laufs, Clare Oliver-Williams, Angela M Wood, Adam S Butterworth,[...]. JAMA 2019
229
13

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.
M H Frick, O Elo, K Haapa, O P Heinonen, P Heinsalmi, P Helo, J K Huttunen, P Kaitaniemi, P Koskinen, V Manninen. N Engl J Med 1987
13

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
Paul M Ridker, Eleanor Danielson, Francisco A H Fonseca, Jacques Genest, Antonio M Gotto, John J P Kastelein, Wolfgang Koenig, Peter Libby, Alberto J Lorenzatti, Jean G MacFadyen,[...]. N Engl J Med 2008
12


Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
11

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.
Min Jun, Celine Foote, Jicheng Lv, Bruce Neal, Anushka Patel, Stephen J Nicholls, Diederick E Grobbee, Alan Cass, John Chalmers, Vlado Perkovic. Lancet 2010
545
10

Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals.
Theingi Aung, Jim Halsey, Daan Kromhout, Hertzel C Gerstein, Roberto Marchioli, Luigi Tavazzi, Johanna M Geleijnse, Bernhard Rauch, Andrew Ness, Pilar Galan,[...]. JAMA Cardiol 2018
335
10

Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.
Marshall B Elam, Henry N Ginsberg, Laura C Lovato, Marshall Corson, Joseph Largay, Lawrence A Leiter, Carlos Lopez, Patrick J O'Connor, Mary Ellen Sweeney, Daniel Weiss,[...]. JAMA Cardiol 2017
76
13

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
Paul M Ridker, Brendan M Everett, Tom Thuren, Jean G MacFadyen, William H Chang, Christie Ballantyne, Francisco Fonseca, Jose Nicolau, Wolfgang Koenig, Stefan D Anker,[...]. N Engl J Med 2017
10

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.
B Mihaylova, J Emberson, L Blackwell, A Keech, J Simes, E H Barnes, M Voysey, A Gray, R Collins, C Baigent. Lancet 2012
10

Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.
A C Keech, P Mitchell, P A Summanen, J O'Day, T M E Davis, M S Moffitt, M-R Taskinen, R J Simes, D Tse, E Williamson,[...]. Lancet 2007
630
10


Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid.
R Preston Mason, Peter Libby, Deepak L Bhatt. Arterioscler Thromb Vasc Biol 2020
84
11


Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.
P M Kearney, L Blackwell, R Collins, A Keech, J Simes, R Peto, J Armitage, C Baigent. Lancet 2008
9

Remnant cholesterol as a causal risk factor for ischemic heart disease.
Anette Varbo, Marianne Benn, Anne Tybjærg-Hansen, Anders B Jørgensen, Ruth Frikke-Schmidt, Børge G Nordestgaard. J Am Coll Cardiol 2013
505
9

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease.
Louise Bowman, Jemma C Hopewell, Fang Chen, Karl Wallendszus, William Stevens, Rory Collins, Stephen D Wiviott, Christopher P Cannon, Eugene Braunwald, Emily Sammons,[...]. N Engl J Med 2017
480
9

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
Colin Baigent, Martin J Landray, Christina Reith, Jonathan Emberson, David C Wheeler, Charles Tomson, Christoph Wanner, Vera Krane, Alan Cass, Jonathan Craig,[...]. Lancet 2011
9

Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial.
Eiichi Araki, Shizuya Yamashita, Hidenori Arai, Koutaro Yokote, Jo Satoh, Toyoshi Inoguchi, Jiro Nakamura, Hiroshi Maegawa, Narihito Yoshioka, Yukio Tanizawa,[...]. Diabetes Care 2018
76
11

Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
Robert P Giugliano, Christopher P Cannon, Michael A Blazing, José C Nicolau, Ramón Corbalán, Jindřich Špinar, Jeong-Gun Park, Jennifer A White, Erin A Bohula, Eugene Braunwald. Circulation 2018
155
9

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
Helen M Colhoun, D John Betteridge, Paul N Durrington, Graham A Hitman, H Andrew W Neil, Shona J Livingstone, Margaret J Thomason, Michael I Mackness, Valentine Charlton-Menys, John H Fuller. Lancet 2004
9

Mechanism of action of fibrates on lipid and lipoprotein metabolism.
B Staels, J Dallongeville, J Auwerx, K Schoonjans, E Leitersdorf, J C Fruchart. Circulation 1998
9

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease.
Frederick E Dewey, Viktoria Gusarova, Richard L Dunbar, Colm O'Dushlaine, Claudia Schurmann, Omri Gottesman, Shane McCarthy, Cristopher V Van Hout, Shannon Bruse, Hayes M Dansky,[...]. N Engl J Med 2017
364
8

Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.
Kausik K Ray, Harold E Bays, Alberico L Catapano, Narendra D Lalwani, LeAnne T Bloedon, Lulu R Sterling, Paula L Robinson, Christie M Ballantyne. N Engl J Med 2019
201
8

Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).
Marc P Bonaca, Patrice Nault, Robert P Giugliano, Anthony C Keech, Armando Lira Pineda, Estella Kanevsky, Julia Kuder, Sabina A Murphy, J Wouter Jukema, Basil S Lewis,[...]. Circulation 2018
314
8

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.
F M Sacks, M A Pfeffer, L A Moye, J L Rouleau, J D Rutherford, T G Cole, L Brown, J W Warnica, J M Arnold, C C Wun,[...]. N Engl J Med 1996
8

Effects of dalcetrapib in patients with a recent acute coronary syndrome.
Gregory G Schwartz, Anders G Olsson, Markus Abt, Christie M Ballantyne, Philip J Barter, Jochen Brumm, Bernard R Chaitman, Ingar M Holme, David Kallend, Lawrence A Leiter,[...]. N Engl J Med 2012
8

Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial.
Kushwin Rajamani, Peter G Colman, Li Ping Li, James D Best, Merryn Voysey, Michael C D'Emden, Markku Laakso, John R Baker, Anthony C Keech. Lancet 2009
165
8

Effects of torcetrapib in patients at high risk for coronary events.
Philip J Barter, Mark Caulfield, Mats Eriksson, Scott M Grundy, John J P Kastelein, Michel Komajda, Jose Lopez-Sendon, Lori Mosca, Jean-Claude Tardif, David D Waters,[...]. N Engl J Med 2007
8

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.
Jackie Bosch, Hertzel C Gerstein, Gilles R Dagenais, Rafael Díaz, Leanne Dyal, Hyejung Jung, Aldo P Maggiono, Jeffrey Probstfield, Ambady Ramachandran, Matthew C Riddle,[...]. N Engl J Med 2012
572
8

Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial.
Michael Miller, Christopher P Cannon, Sabina A Murphy, Jie Qin, Kausik K Ray, Eugene Braunwald. J Am Coll Cardiol 2008
392
8

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
8

Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials.
Nicholas A Marston, Robert P Giugliano, KyungAh Im, Michael G Silverman, Michelle L O'Donoghue, Stephen D Wiviott, Brian A Ference, Marc S Sabatine. Circulation 2019
66
12


Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial.
Matthew J Budoff, Deepak L Bhatt, April Kinninger, Suvasini Lakshmanan, Joseph B Muhlestein, Viet T Le, Heidi T May, Kashif Shaikh, Chandana Shekar, Sion K Roy,[...]. Eur Heart J 2020
88
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.